Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + cisplatin + S-1 + CRS + HIPEC
- Development stage
- Unknown
- Lead developer
- Yonsei University
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Oral
01
Overview
CRS + HIPEC-Yonsei University-gastric cancer-peritoneal metastasis refers to a multimodal treatment regimen evaluated by Yonsei University for the management of gastric cancer with peritoneal seeding. The protocol involves cytoreductive surgery (CRS) to remove all visible peritoneal tumors, followed by extensive peritoneal lavage (EPL) and hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin and paclitaxel. The treatment is completed with postoperative intraperitoneal chemotherapy (paclitaxel and cisplatin) and oral S-1. This approach combines the mechanical removal of tumor mass with the synergistic effects of heat and high-dose regional chemotherapy to target microscopic residual disease and improve survival outcomes in a patient population with traditionally limited therapeutic options.
- Other names
- CRS + HIPEC-Yonsei University-gastric cancer-peritoneal metastasisCRS + EPL + HIPEC + IP chemotherapyYonsei University gastric cancer peritoneal metastasis regimen
02
Targets
DPYD (Dihydropyrimidine dehydrogenase)TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on paclitaxel + cisplatin + S-1 + CRS + HIPEC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + cisplatin + S-1 + CRS + HIPEC.